Grant: Applied Research and Development Grants - Level 1

It is common for patients to develop immunity against the majority of protein-based therapeutics and gene therapies, which results in the loss of treatment. For instance, 30% of patients with Hemophilia A become immune against their protein-based therapy and nearly 100% of patients receiving gene therapy become immune, preventing a second dose. *Serenity Bioworks is a Canadian biotech company located in Kitchener (Ontario) with a focus on developing novel formulations for protein-based therapeutics and gene therapies. They are examining the potential for its formulations to modulate the immune system, creating a state of tolerance towards protein-based therapeutics and gene therapy products. In collaboration with Lambton College's Bioindustrial Process Research Centre they propose to develop and optimize a protein purification methodology to improve the yield of their protein products.*The proposed project's research team will include a project lead, research technician and research student who will work closely with Serenity Bioworks. The results of this project will enable Serenity to develop a product that could potentially improve the standard of care for millions of Canadians that currently use protein-based therapeutics and/or Canadians that will be using gene therapy products.